Abstract Number: 1695 • ACR Convergence 2020
Anti-Melanoma Differentiation Associated Protein 5 (MDA5) Positive Juvenile Dermatomyositis: Focus on the Lung
Background/Purpose: A subset of juvenile dermatomyositis (JDM), clinically amyopathic dermatomyositis (CADM), is uncommon and mainly described in adults. CADM is classically characterized by skin ulcerations,…Abstract Number: 0713 • ACR Convergence 2020
Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients with JIA has been demonstrated…Abstract Number: 0737 • ACR Convergence 2020
“It’ll Go Away. There’s Nothing Wrong with you:” the Experience of Pain-Related Stigma Among Adolescents with Pain Amplification Syndrome
Background/Purpose: Chronic pain in adolescence is a complex and significant medical condition, with a reported prevalence of 11-38%.1 Pain amplification syndrome (PAS), which includes fibromyalgia,…Abstract Number: 1169 • ACR Convergence 2020
Three-Dimensional Analysis of Facial Asymmetry in Craniofacial Scleroderma
Background/Purpose: Localized scleroderma (LS) is a rare, progressive autoimmune disease of the skin and underlying connective tissue that can result in devastating functional impairment and cosmetic damage in children. …Abstract Number: 1612 • ACR Convergence 2020
Assessing Patient Self-Reported Transition Readiness in a Large Pediatric Rheumatology Center
Background/Purpose: Pediatric rheumatology patients need effective transition from pediatric to adult providers. Texas Children’s Hospital (TCH) rheumatology clinic providers have developed a transition pathway, the…Abstract Number: 1678 • ACR Convergence 2020
Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis
Background/Purpose: Renal involvement is reported in up to 80% of juvenile systemic lupus erithematosus (JSLE) and its among the most severe manifestations in these population. Antimalarials are one of…Abstract Number: 1778 • ACR Convergence 2020
Improving Teratogenic Medication Consent and Sexual Activity Screening in Adolescent and Young Females: A Pediatric Rheumatology Reproductive Health Initiative
Background/Purpose: Adolescent and young women with rheumatic diseases are often prescribed teratogenic medications to manage their disease. Published reports indicate that the frequency of reproductive health counseling…Abstract Number: 0714 • ACR Convergence 2020
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…Abstract Number: 0937 • ACR Convergence 2020
Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study
Background/Purpose: Kawasaki disease (KD) is a common childhood vasculitis associated with coronary artery aneurysms (CAA). Based on our recent work, the incidence of KD has…Abstract Number: 1171 • ACR Convergence 2020
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests. Results from the Juvenile Scleroderma Inception Cohort
Background/Purpose: Juvenile systemic sclerosis (jSSc) has a prevalence in around 3 in a million children. Pulmonary involvement occurs in approximately 40 % in the international…Abstract Number: 1613 • ACR Convergence 2020
Improving Transition Policy Dissemination and Care Team Communication in Pediatric Rheumatology Clinic Through Standardization of Workflow and Electronic Health Record Documentation
Background/Purpose: Morbidity and mortality increase when young adults with chronic disease transfer from pediatric to adult care. Structured healthcare transition processes improve outcomes, yet are…Abstract Number: 1679 • ACR Convergence 2020
Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis
Background/Purpose: Corticosteroids (CS) remain the mainstay of therapy for childhood-onset systemic lupus erythematosus (cSLE). However, widely accepted strategies for oral (PO) or intravenous (IV) CS…Abstract Number: 1787 • ACR Convergence 2020
Differences in Chromatin Architecture Between Treatment Naïve Pediatric and Adult Lupus Patients
Background/Purpose: Systemic lupus erythematosus (SLE) is possibly triggered by gene-environment interactions. We showed most of the SLE haplotypes encompass genomic regions enriched for epigenetic marks…Abstract Number: 0717 • ACR Convergence 2020
Predictors of Clinical Remission in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis Treated with Etanercept in the CLIPPER Studies
Background/Purpose: CLIPPER is an ongoing, 8-year, phase 3b, multicenter, open-label study of the safety and efficacy of etanercept in the treatment of juvenile idiopathic arthritis…Abstract Number: 0957 • ACR Convergence 2020
Mitochondrial ROS as a Regulator of Calcinosis in Juvenile Dermatomyositis
Background/Purpose: Calcinosis, the accumulation of calcium crystals in soft tissues, is often a locus of infection and a debilitating manifestation of chronic juvenile dermatomyositis (JDM),…
- « Previous Page
- 1
- …
- 45
- 46
- 47
- 48
- 49
- …
- 62
- Next Page »